Analysts have been eager to weigh in on the NA sector with new ratings on Unum Therapeutics Inc (NASDAQ:UMRX) and Homology Medicines Inc (NASDAQ:FIXX).
Unum Therapeutics Inc (UMRX)
In a report released today, Marc Frahm from Cowen & Co. maintained a Hold rating on Unum Therapeutics Inc. The company’s shares opened today at $15.62.
According to TipRanks.com, Frahm is a 1-star analyst with an average return of -4.2% and a 20.0% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Blueprint Medicines.
The the analyst consensus on Unum Therapeutics Inc is currently a Hold rating.
See today’s analyst top recommended stocks >>
Homology Medicines Inc (FIXX)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Homology Medicines Inc today. The company’s shares opened today at $15.67, close to its 52-week low of $15.22.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.2% and a 55.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Homology Medicines Inc.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
